Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease.
We examined in Sprague-Dawley rats whether intranigral administration of complex-I inhibitor, rotenone, produces biochemical lesions in the striatum similar to those observed in Parkinson's disease (PD). Unilateral stereotaxic infusion of rotenone (2-12 mug in 1 mul) into substantia nigra (SN) pars compacta caused significant inhibition of complex-I activity and increased production of hydroxyl radicals in vivo as measured employing spectrophotometric and HPLC-electrochemical procedures, respectively. It also caused a significant time- and dose-dependent reduction of dopamine level, but not serotonin, in the ipsilateral striatum when assayed using an HPLC electrochemical method. This effect was found to be progressive for 90 days. A dose-dependent decrease in nigral glutathione level, as measured fluorimetrically, was also observed to be progressive till 90th day. A significant decrease in tyrosine hydroxylase immunoreactivity in the striatum (73 +/- 8.4% as assessed by densitometric studies) or in SN ipsilateral to the side of infusion suggested nigrostriatal neuronal degeneration. A dose of rotenone (6 microg in 1 microl) that caused 55% striatal dopamine depletion when infused into the SN failed to affect serotonin levels in the terminal regions when infused into the nucleus raphe dorsalis, indicating rotenone's specificity of action towards dopaminergic neurons. Our findings suggest that unilateral infusion of rotenone reproduces neurochemical and neuropathological features of hemiparkinsonism in rats and indicate an active involvement of oxidative stress in rotenone-induced nigrostriatal neurodegeneration. The present study also demonstrates more sensitivity of dopaminergic neurons towards rotenone and establishes mitochondrial complex-I damage as one of the major contributory components of neurodegeneration in PD. The progressive nature of pathology in this model closely mimics idiopathic PD, and absence of mortality warrants the use of this model in drug discovery programs.
Saravanan
Karuppagounder S
KS
Division of Clinical and Experimental Neuroscience, Indian Institute of Chemical Biology, 4, Raja S. C. Mullick Road, Calcutta 700 032, India.
Sindhu
Kizhakke M
KM
Mohanakumar
Kochupurackal P
KP
D033942:Adaptor Proteins, Vesicular Transport; D000704:Analysis of Variance; D000818:Animals; D001479:Basal Ganglia / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology*; D015306:Biogenic Monoamines / Q000378:metabolism; D002396:Catechols / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004305:Dose-Response Relationship, Drug; D005978:Glutathione / Q000378:metabolism; D006878:Hydroxides / Q000378:metabolism; D062385:Hydroxybenzoates; D007150:Immunohistochemistry / Q000379:methods; D008297:Male; D009419:Nerve Tissue Proteins / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012402:Rotenone / Q000633:toxicity*; D013378:Substantia Nigra / Q000187:drug effects*; D013997:Time Factors; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism; D014475:Uncoupling Agents / Q000633:toxicity*
D033942:Adaptor Proteins, Vesicular Transport; D015306:Biogenic Monoamines; D002396:Catechols; D006878:Hydroxides; D062385:Hydroxybenzoates; D009419:Nerve Tissue Proteins; D014475:Uncoupling Agents; C095992:complexin I; D012402:Rotenone; C009135:2,3-dihydroxybenzoic acid; C031356:hydroxide ion; D014446:Tyrosine 3-Monooxygenase; D005978:Glutathione